Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03878888 · ClinicalTrials.gov registry record · Phase 4
Exparel Use in Bilateral TAP Blocks for Postoperative Pain Control
A Phase 4 study, sponsored by St. Luke's Hospital, Pennsylvania.
- Completed
- Registry status
- Phase 4
- Development phase
- 52
- Enrollment target
NCT03878888 is a Phase 4 study that has completed, run by St. Luke's Hospital, Pennsylvania. The registered enrollment target is 52 participants.
The verdict
NCT03878888, a Phase 4 study, has completed, sponsored by St. Luke's Hospital, Pennsylvania.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 52 participants
- Enrollment target
Study Summary
To determine if Exparel (Liposomal Bupivacaine, an FDA approved drug) use in ultrasound guided Transversus Abdominis Plane (TAP) blocks may reduce opioid requirement use postoperatively, reduce pain scores postoperatively, reduce incidence of nausea in the postop period, and decrease length of hospital stay
Interventions
- DRUG Exparel 266 MG Per 20 ML Injection
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 52 participants |
| Start Date | 2019-01-15 |
| Est. Completion | 2019-07-01 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03878888
The ClinicalTrials.gov registry entry for NCT03878888 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 52 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is St. Luke's Hospital, Pennsylvania, which has 10 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Exparel 266 MG Per 20 ML Injection is the first listed.
NCT03878888 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03878888 about?
NCT03878888 is a clinical study titled "Exparel Use in Bilateral TAP Blocks for Postoperative Pain Control". To determine if Exparel (Liposomal Bupivacaine, an FDA approved drug) use in ultrasound guided Transversus Abdominis Plane (TAP) blocks may reduce opioid requirement use postoperatively, reduce pain scores postoperatively, reduce incidence of nausea in the postop period, and decrease length of hospi...
What is the current status of trial NCT03878888?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 52 participants. The study started on 2019-01-15. Estimated completion is 2019-07-01.
What interventions are being tested in trial NCT03878888?
The interventions under investigation include: Exparel 266 MG Per 20 ML Injection (DRUG).
Who is sponsoring clinical trial NCT03878888?
This trial is sponsored by St. Luke's Hospital, Pennsylvania, which has 10 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.